#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Significance of C kit and MYB Gene Expression for Diagnosis, Prognosis and Treatment of Adenoid Cystic Carcinoma of the Salivary Glands- the Current Level of Research and Its Application in Clinical Practice


Authors: M. Brož;  I. Stárek;  Richard Salzman
Authors place of work: Klinika otorinolaryngologie a chirurgie hlavy a krku LF UP a Fakultní nemocnice Olomouc
Published in the journal: Otorinolaryngol Foniatr, 65, 2016, No. 1, pp. 53-57.
Category: Review Article

Summary

Adenoid cystic carcinoma is the second to third most common malignant tumor of major and predominant neoplasm of minor salivary glands. Along with some other salivary carcinomas, ACC is characterized with difficulties in the prediction of its clinical course. Consequently, new prognostic and predictive molecular biomarkers are being sought. This mainly concerns the identification of genes and related products, responsible for the initiation, progression and metastasizings of tumors. Furthermore, it is supposed that the targeted biological blockade could improve survival curves of high grade salivary tumors associated with dismal prognosis.

This paper reviews the role of C-kit and MYB genes, in recent years intensively studied genetic alterations in diagnosis, prognosis and targeted treatment of adenoid cystic carcinoma of salivary glands.

Keywords:
C kit, MYB, adenoid cystic carcinoma, salivary gland, prognosis, targeted therapy


Zdroje

1 Alcedo, J. C., Fabrega, J. M., Arosemena, J. R. et al.: Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck, 26, 2004, s. 829-831.

2. Andreadis, D., Epivatianos, A. et al.: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncology, 42, 2006, s. 57-65.

3. Argiris, A., Feinstein, T. M., Wang, L.: Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational new drugs, 30, 2012, 4, s. 1575-1584.

4. Bell, D., Roberts, D. et al.: Cell type dependent biomarker expression in adenoid cystic carcinoma. Cancer, 116, 2010, s. 5749-5056.

5. Bell, D., Roberts, D., Karpowicz, M., Hanna et al.: Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer biology & Therapy, 12, 2011, 7, s. 569-573.

6. Bradley, P. J., Orlando, G. L.: Salivary gland disorders and diseases: diagnosis and management. Georg. Thieme Verlag, 2011, s. 256.

7. Brill, L., Kanner, W.: Analysis of MYB expression and MYB-NFIB gene fusion in adenoid cystic carcinoma and other salivary neoplasms. Modern Pathology, 24, 2011, s. 1169-1176.

8. Cross, R. S., Malaterre, J., Davenport, A. J. et al.: Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clinical & Translational Immunology, 4, 2015, 1, e30.

9. Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors. www.clinicaltrials.gov.

10. Faivre, S., Raymond, E., Casiraghi et al.: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. Journal of Clinical Oncology, 23, 2005, s. 6271-6273.

11. Gondivkar, S. M. Gadbail, A. R., Chole, R., Parikh, R. V.: Adenoid cystic carcinoma: a rare clinical entity and literature review. Oral Oncology, 47, 2011, 4, s. 231-236.

12. Ghosal, N., Mais, K., Shenjere, P. et al.: Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. British Journal of Oral and Maxillofacial Surgery, 49, 2011, 7, s. 510-515.

13. Heinrich, M., Joensuu, H., Demetri. G. et al.: Phase II, Open-label study evaluating the activity of imatinib in treating Life-threatening malignancies known to be associated with Imatinib-sensitive tyrosine kinases .Clin. Cancer, 14, 2008, s. 2717-2725.

14. Hotte, S. J., Winquist, E. W., Lamont, E. et al.: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J. Clin. Oncol., 23, 2005, s. 585-590.

15. Chau, N. G., Hotte, S. J., Chen, E. X. et al.: A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Annals of Oncology, 23, 2005, s. 1562-1570.

16. Klener, P., Klener, P. jr.: Nová protinádorová léčiva a  léčebné strategie v onkologii. Grada Publishing, Praha, I. vydání, 2010.

17. Lin, H., Yen, F. et al.: Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head & Neck, 12, 2005, s. 1022.

18. Marchiò, C., Weigelt, B., Reis-Filho, J.: Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas). J. Clin. Pathol., 63, 2010, s. 220-228.

19. Miettinen, M., Lasota, J.: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of Pathology & Laboratory Medicíně, 130, 2006, 10, s. 1466-1478.

20. Milano, A., Longo, F., Basile, M. et al.: Recent advances in the treatment of salivary gland cancers: Emphasis on molecular targeted therapy .Oral Oncology, 43, 2007, s. 729-734.

21. Mino, M., Pilch, B. Z., Faquin, W. C.: Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Modern Pathology, 16, s. 1224-1231.

22. Mitani, Y., Rao, P. H., Futreal, A. et al.: Novel chromosomal rearrangements and bvreak points at the t(6;9) in salivary adenoid cystic carcinoma: Association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clinical Cancer Research, 17, 2011, s. 7003-7014.

23. Mitani, Y., Li, J., Rao H. et al.: Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma : incidence ,variability and clinicopathological significance. Clin. Cancer Res., 16, 2010, s. 4722-4731.

24. Pattabiraman, D. R., Gonda, T. J.: Role and potential for therapeutic targeting of MYB in leukemia. [Review] Leukemia, 27, 2013, 2, s. 269-277.

25. Persson, M., Andrén, Y., Mark, J. et al.: Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proceedings of the National Academy of Sciences, 106, 2009, 44, s. 18740-18744.

26. Pfeffer, M. R., Talmi, Y., Catane, R. et al.: A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol., 43, 2007, s. 33-36.

27. Pusztaszeri, M. P., Sadow, P. M., Ushiku, A. et al.: MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens. Cancer Cytopathology, 122, 2014, 4, s. 257-265.

28. Ramsay, R. G., Barton, A. L., Gonda, T. J.: Targeting c-Myb expression in human disease. Expert Opinion on Therapeutic Targets, 7, 2003, 2, s. 235-248.

29. Seethala, R. R.: An update on grading of salivary gland carcinomas. Head and Neck Pathology, 2009, 3, s .69-77.

30. Seethala, R. R, Hunt, J. L., Baloch, Z. W., LiVolsi, V. A., Barnes, E. L.: Adenoid cystisc carcinoma with high-grade transformation. A report of 11 cases and review of the literature. Am. J. Surg. Pathol., 31, 2007, 11, s. 1683-1694.

31. Skalova, A.,Vanecek, T., Sima, R. et al.: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol., 34, 2010, s. 599-608.

32. Slamon, D. J., Boone, T. C., Murdock, D. C. et al.: Studies of the human c-myb gene and its product in human acute leukemias. Science, 233, 1986, s. 347-351.

33. Sørensen, K., Godballe, Ch., Stricker, K. et al.: Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. Journal of Oral Pathology & Medicine, 35, 2006, s. 286-291.

34. Speight, P. M., Baret, A. W.: Salivary gland tumours. Oral Diseases, 2002, 8, s. 229-240.

35. Stapiro, R. H, Huvos, G. A.: Stage means more than grade in adenoid cystic carcinoma. The American Journal of Surgery, 164, 1992, 6, s. 623-628.

36. Stárek, I., Kučerová, L., Skálová, A.: Imunohistochemická exprese C-kit onkoproteinu u karcinomů slinných žláz (pilotní studie) .Otorinolaryngologie a foniatrie, 2010, 3, s. 129-135.

37. Szanto, P. A., Luna, M. A., Tortoledo, M. E. et al.: Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancor, 54, 1984, 6, s. 1062-1069.

38. Taniguchi, M., Nishida, T., Sirota, S., Isozak, K. et al.: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Research, 59, 1999, s. 4297-4300.

39. West, R. B., Kong, C., Clarke, N., Gilks, T.: MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. The American Journal of Surgical Pathology, 35, 2011, 1, s. 92-99.

40. Wilkins, H. R., Doucet, K., Duke, V., Morra, A., Johnson, N.: Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein and decreasing transcription of the antiapoptotic protein bcl-2. Tumour Biol., 31, 2010, s. 16-22.

Štítky
Audiology Paediatric ENT ENT (Otorhinolaryngology)
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#